Who is sponsoring NCT00171132?

NCT00171132 is sponsored by Novartis.

What condition does NCT00171132 study?

NCT00171132 studies Hypertension.

What drugs are being tested in NCT00171132?

Interventions: valsartan, atenolol, hydrochlorothiazide.

What is the status of NCT00171132?

NCT00171132 is currently COMPLETED.

Last reviewed 2017-02-21 · How we verify

A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance

NCT00171132 Phase 4 COMPLETED

The purpose of the study is to show that valsartan compared to atenolol has favorable effects on exercise capacity, quality of life, diastolic function and elevated blood pressure in hypertensive postmenopausal overweight women with impaired exercise tolerance despite normal left ventricular ejection fraction (LVEF).

Details

Lead sponsor	Novartis
Phase	Phase 4
Status	COMPLETED
Enrolment	64
Start date	2004-08
Completion	2007-08

Conditions

Hypertension

Interventions

valsartan
atenolol
hydrochlorothiazide

Primary outcomes

Change from baseline in exercise capacity measured by oxygen consumption during exercise testing, after 26 weeks

Countries

Germany, Switzerland